Program
repinatrabit
Also written as “JNT-517 Tablet”, “JNT-517” and “Repinatrabit”.
Its studies are mostly in Phenylketonurias, led by Otsuka.
Furthest: phase 3, since Oct 2, 20247 company-led studies, 4 open or runningNext primary completion: Feb 9, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsuka | 74 open or running | phase 3since Oct 2, 2024 | Feb 11, 2023 | Feb 9, 2027phase 1 · NCT07713758 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 11, 2023First study: phase 2 study in PhenylketonuriasFirst studyNCT05781399 · 163 enrolled · United States, Australia
- Oct 2, 2024Phase 3 study in PhenylketonuriasNCT06628128 · 240 planned · United States, Australia
- Oct 7, 2024Phase 2 study in PhenylketonuriasNCT06637514 · 14 enrolled · United States, Australia
- May 7, 2025Phase 3 study in PhenylketonuriasNCT06971731 · 120 planned · United States, Australia, Canada and more
- Feb 25, 2026Phase 1 study in PhenylketonuriasNCT07446400 · 48 planned · Australia
- Apr 30, 2026Phase 1 study in Healthy VolunteersNCT07573449 · 8 enrolled · United States
- Jul 15, 2026Phase 1 study in PhenylketonuriasNCT07713758 · 32 planned · United States
Ahead
- Nov 7, 2026Primary completion: phase 1 study in PhenylketonuriasNCT07446400
- Feb 9, 2027Primary completion: phase 1 study in PhenylketonuriasNCT07713758
- Nov 1, 2027Primary completion: phase 3 study in PhenylketonuriasNCT06628128
- Mar 1, 2028Primary completion: phase 3 study in PhenylketonuriasNCT06971731
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07713758Phenylketonurias · United States | 1 | Recruiting | Feb 9, 2027 | 32 |
| NCT07573449Healthy Volunteers · United States | 1 | Completed | Jan 22, 2025 | 8 |
| NCT07446400Phenylketonurias · Australia | 1 | Recruiting | Nov 7, 2026 | 48 |
| NCT06971731Phenylketonurias · United States, Australia, Canada and more | 3 | Recruiting | Mar 1, 2028 | 120 |
| NCT06637514Phenylketonurias · United States, Australia | 2 | Completed | May 8, 2026 | 14 |
| NCT06628128Phenylketonurias · United States, Australia | 3 | Recruiting | Nov 1, 2027 | 240 |
| NCT05781399Phenylketonurias · United States, Australia | 2 | Completed | Jul 29, 2025 | 163 |
How it is read
Names in the registry
- “JNT-517 Tablet”, 3 entries
- “JNT-517”, 2 entries
- “Repinatrabit”, 2 entries
- “JNT-517 Suspension”, 1 entry
- “[14C]-JNT-517”, 1 entry
Conditions, from the studies’ own filings
- Phenylketonurias, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.